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Abstract
Introduction: Breast carcinoma is the main malignant tumor occurring in patients with Cowden disease, a cancer-
prone syndrome caused by germline mutation of the tumor suppressor gene PTEN characterized by the
occurrence throughout life of hyperplastic, hamartomatous and malignant growths affecting various organs. The
absence of known histological features for breast cancer arising in a PTEN-mutant background prompted us to
explore them for potential new markers.
Methods: We first performed a microarray study of three tumors from patients with Cowden disease in the
context of a transcriptomic study of 74 familial breast cancers. A subsequent histological and immunohistochemical
study including 12 additional cases of Cowden disease breast carcinomas was performed to confirm the microarray
data.
Results: Unsupervised clustering of the 74 familial tumors followed the intrinsic gene classification of breast cancer
except for a group of five tumors that included the three Cowden tumors. The gene expression profile of the
Cowden tumors shows considerable overlap with that of a breast cancer subgroup known as molecular apocrine
breast carcinoma, which is suspected to have increased androgenic signaling and shows frequent ERBB2
amplification in sporadic tumors. The histological and immunohistochemical study showed that several cases had
apocrine histological features and expressed GGT1, which is a potential new marker for apocrine breast carcinoma.
Conclusions: These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of
tumorigenesis promotes the formation of breast tumors with apocrine features.
Introduction
The classification of breast cancer was recently enriched
by the addition of gene expression microarray data for
the main histopathological tumor types [1]. The most
widely used transcriptomic classification, the Intrinsic
Gene Set or Stanford classification, divides breast cancer
into luminal A, luminal B, basal-like, normal-like and
HER2 classes [2-4]. It is based on studies of sporadic
tumors, and reflects mainly tumor cell type and HER2
status. Few studies have looked at the gene expression
profile of breast cancers arising in patients with a famil-
ial predisposition to cancer. In those studies, the tumors
arising in patients with germline BRCA1 mutations fre-
quently had a basal-like phenotype, whereas BRCA2-
related tumors had no particular type or a luminal B
type [5]. Little is known about the transcriptomic profile
of breast cancers caused by germline mutations in genes
other than BRCA1 and BRCA2. Cowden disease (MIM
158350) is a cancer predisposition syndrome caused by
germline mutation of the tumor suppressor gene PTEN
[6,7]. In addition to hamartomas and hyperplasias affect-
ing multiple organs, patients develop breast cancer with
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a cumulative risk > 50% at age 70 [8]. To investigate the
pathogenesis of breast cancer in Cowden disease, we
have analyzed the gene expression profile of three breast
carcinomas from Cowden disease patients with known
germline PTEN mutations.
Materials and methods
Patients and samples
To allow us to identify distinctive features of PTEN-
related tumors, the analysis was performed in the context
of a panel of 74 tumors from patients with a familial clus-
tering of breast cancer, including 7 with BRCA1 and 5
with BRCA2 mutations. All of the samples were taken
from the Bergonié Cancer Institute tumor bank. The
patients belong to families with either i) at least three
cancer affected first degree relatives including at least
two with breast cancer; or ii) two first degree relatives
with breast cancer at a young age of onset (mean age up
to 50 years). Only one tumor sample per patient was
tested. In most cases only one tumor was available per
family, but in one family, three samples were available,
and in seven other families, including one Cowden
family, two samples were available. Major demographic,
clinical and pathological features are listed in Table S1 in
Additional file 1. All patients agreed to the use of their
samples for research purposes, in compliance with the
French law on tumor banks (law n° 2004-800). The
PTEN mutation search was made after signed informed
consent in the context of a medical genetic diagnosis of
suspected Cowden disease, in compliance with the
French law on genetic testing (law n° 94-654).
Gene expression analysis
After assessment of tumor cellularity in each sample on
haematoxylin-eosin stained frozen sections, Rneasy Mini
Kits (Qiagen S.A., Courtaboeuf, France) were used to
extract total RNA from samples ground to powder while
frozen. RNA quality was assessed using the Agilent 2100
Bioanalyzer (Agilent Technologies France, Massy,
France). Gene-expression analyses were performed by
the IGBMC and Génopole Alsace-Lorraine Affymetrix
service using Affymetrix U133 Plus 2.0 genechip micro-
arrays(Affymetrix UK Ltd, High Wycombe, UK). The
transcriptomics data are available in ArrayExpress data-
base [9] - (accession number: [E-TABM-854]) or in the
CIT database [10].
Mutation analysis
DNA was purified from leucocytes and tumors by phenol-
chloroform extraction. PTEN point mutations were identi-
fied by denaturing gradient gel electrophoresis (DGGE)
screening followed by sequencing of the variants on an
ABI DNA sequencing machine [11]. Large rearrangements
were screened for by quantitative multiplex PCR [12].
Immunohistochemistry
Immunohistochemical detection was performed with the
REAL EnVision Detection System (Dako®, Trappes,
France). Tissue microarraying was performed with a tis-
sue arrayer (MTA Booster 01, Alphelys, Plaisir, France).
For each sample, four 0.6 mm core sections of tissue
were extracted from paraffin-embedded tissues. The fol-
lowing antibodies were used: anti-GGT1 (Sigma-
Aldrich® St. Louis, MO, USA, clone 1F9); anti-PTEN
(Cascade Biosciences™ Winchester, MA, USA, clone
6H2.1); anti-Estrogen receptor (Dako® Trappes, France,
clone 1D5); anti-Progesterone receptor (Dako®, Trappes,
France, clone PgR636); anti-HER2 (Dako®, Trappes,
France, cloneAO485); anti-Androgen Receptor (Dako®
Trappes, France, clone 1D5); anti-GCDFP15 (Signet™,
Dedham, MA, USA, clone D6); anti-EGFR (Ventana®, Ill-
krich, France, clone 3C6). Two parameters were evalu-
ated for each antibody: (i) the percentage of tumoral
cells showing a positive signal and (ii) the intensity of
that signal classed as low (1), moderate (2) or high (3).
ERBB2 expression was evaluated according to the Her-
ceptest scoring system. For ER, PR, AR, PTEN,
GCDFP15, GGT1 and EGFR, the following scoring was
used: score 0, no tumor cells with any positivity; score1,
1 to 10% of tumors cells showing a positive signal; score
2, 11 to 100% of tumor cells showing a positive signal,
whatever associated intensity of staining.
Array CGH analyses
Array CGH was performed on human Integrachip V7
slides (Integragen SA, Evry, France, [13]). IntegraChip
V7 is composed of 5878 BAC clones with a median of
0.5 Mb between clones. BAC clones are spotted in
quadruplicate. A pool of 19 normal DNAs was used as
reference DNA. DNA was labelled by random priming
with cyanine 5 for reference DNA (Cy5) and cyanine 3
for tumor DNA (Cy3). Hybridizations were performed
according to the manufacturer’s recommendations.
Slides were scanned with an Axon 4000B scanner (Axon
Instruments Inc., Union City, CA, USA) and acquired
images were analyzed with GenePix Pro 5.1 image ana-
lysis software to perform segmentation and to determine
the mean intensities for the Cy3 and Cy5 signals of each
BAC clone.
The CAPweb (Copy number Array analysis Platform
on the web) platform developed by Institut Curie [14]
was used for normalization (MANOR package), gain,
loss or normal clone status assignment and breakpoint
detection (GLAD package). The following default filter-
ing parameters were retained: signal to noise ratio less
than 3, standard deviation of replicates greater than 0.1
and exclusion of clones with missing values in over 50%
of the tumors. Graphical representation of genomic
alterations was performed with VAMP software (Institut
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Curie, Paris, France) [15,16]. The definition of gains and
losses was based on median Cy3 to Cy5 log ratios
greater than 1.2 and less than 0.8 respectively. Ampli-
cons were defined by median log ratios greater than 2.
The array CGH data are available in the ArrayExpress
database (accession number: E-TABM-854) [9] or in the
CIT database [10].
Statistical analyses
Except where indicated, all transcriptomic analyses were
carried out using R packages [17,18] or original R code.
Raw gene expression data were normalized using the
robust multi-array average (RMA) method from the R
package affy [19]. Probe sets for control genes and those
for which the 90th percentile of the log2 intensity was <
10 were removed, yielding a total of 48,927 probe sets.
Unsupervised classification of samples
Probe sets were selected for clustering based on the fol-
lowing criteria: (i) P-value of a variance test less than
0.01 and (ii) a robust coefficient of variation (rCV) less
than 10 but greater than the 95th percentile of the rCV.
For the variance test, we selected probe sets (P) whose
variance across the samples was different from the med-
ian of the variances (Varmed) of all the probe sets. The
statistic used was (n-1)´Var(P)/Varmed, where n refers
to the number of samples. This statistic was compared
to a percentile of the Chi-square distribution with (n-1)
degrees of freedom and yielded a P-value for each probe
set. This criterion is the same as that used in the filter-
ing tool of the BRB ArrayTools software [20]. The rCV
was calculated as follows: having ordered the intensity
values of the n samples from minimum to maximum,
we eliminated the minimum and maximum values and
calculated the coefficient of variation for the remaining
values. After filtering, we were left with 2,447 probe sets
which were used for agglomerative hierarchical cluster-
ing using Ward’s linkage and 1-Pearson correlation as a
distance metric. The resulting dendrogram is used to
order the genes and samples in the heatmap in Figure 1.
Assignment of samples to Stanford classes
In order to assign the tumor samples to the five sub-
types in the Stanford classification, we calculated the
Pearson correlation between each sample and each of
the five centroids [4,21]. The probe sets in the two data-
sets were matched based on the UniGene IDs, resulting
in a total of 334 common genes. Samples were then
assigned to the subtype of the centroids with the largest
correlation coefficient; this procedure is generally
referred to as Sorlie’s centroid prediction. The same pro-
cedure was applied to assign the tumor samples to the
five subtypes in the Hu et al. classification [2], with a
set of 213 common genes.
The Cowden signature was obtained by applying a
Welch T-test comparing the samples in the Cowden
cluster to all the other samples for the 48,927 probe
sets retained after filtering. We selected the 3,075 probe
sets with a P-value < 0.01 corresponding to a local
False-Discovery-Rate of 20% (R package kerfdr [22]),
then applied a random-forest procedure to choose the
200 probe sets best able to divide the samples into two
groups, with a P-value < 0.001 (R package randomForest
[23]) These 200 probe sets are the Cowden signature
probe sets.
Gene set analysis
To define gene sets for pathway analysis, we mapped the
biological pathway-related genes, gene ontology (GO)
term-related proteins and public gene signatures to
non-redundant Entrez Gene identifiers. For each GO
term, we obtained a non-redundant list of protein iden-
tifiers, either directly associated with the GO term or
one of its descendants, and mapped it to a non-redun-
dant list of Entrez Gene ids, GO terms and their rela-
tionships (parent/child) [24]. Public signatures were
downloaded from the molecular signature database
MSigDB [25,26]. We used the hypergeometric test to
measure the association between the Cowden signature
(Entrez Gene ids) and a biological pathway, a GO term
or a public signature, as described in the GOstats R
package.
Principal components analysis
The first two principal components were used to visua-
lize the tumors (ade4 R [27]). The groups of samples
identified visually were confirmed by model-based clus-
tering (R package mclust [28]). The signature showing
transcriptomic differences between Cowden and non-
Cowden molecular apocrine carcinomas was obtained
by applying a Welch T-test to the three Cowden tumors
and the two apocrine non-Cowden tumors following the
same approach as that for the determination of the
Cowden signature.
Statistical tests
Association of the sample subgroups to bio-clinical fac-
tors and to immunohistochemical factors was evaluated
by applying a chi-square test (or the equivalent Fisher-
exact test when appropriate).
The genomic rate of perturbation was defined as the
mean, by chromosomal arm, of the ratio between the
number of clones lost or gained and the total number of
informative clones for each arm.
Results
Cowden tumors cluster together
The heatmap obtained after unsupervised clustering of
the gene expression data from 74 tumors from
patients with a familial clustering of breast cancer is
shown in Figure 1. The major branches in the dendro-
gram correspond to the luminal A, luminal B and
basal-like classes in the Stanford classification [4]
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(P = 2.4 × 10-18 with the Sorlie intrinsic gene set and
P = 1.3 × 10-22 with the Hu intrinsic gene set). Inter-
estingly, the three Cowden tumors, along with two
supplementary tumors, lie on a separate branch,
marked orange in the figure, characterized by over-
expression of a group of about 84 genes (cluster e,
Figure 1). Correlation with the Stanford centroids [4]
was used to classify these tumors. Two were assigned
to the HER2 class and three to the normal-like class,
indicating that the observed clustering can not be
explained by the Stanford model. The two non-Cow-
den tumors were tested for somatic point mutations
and large rearrangements in the PTEN gene, but no
abnormalities were detected.
Figure 1 Unsupervised hierarchical clustering of familial breast cancers. Unsupervised hierarchical clustering using 2,447 highly variable
probe sets. The orange branch contains the molecular apocrine tumors and includes the three Cowden tumors. PTEN: Germline PTEN mutation
status (black box: wild type; white box: mutated). ESR1, PGR, AR: estrogen, progesterone and androgen receptor status determined by
immunohistochemical staining [black box: positive (that is, score 2); white box: negative (that is, score 0 and 1 - see material and methods)].
Sorlie: The colored boxes represent the Stanford intrinsic gene classification based on the centroids described by Sorlie et al. [4] (red, basal-like
class; pink, HER2 class; green, normal-like class; dark blue, luminal A class; light blue, luminal B class). Hu: same classification based on the revised
centroids [2].
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The Cowden signature is similar to a molecular apocrine
signature
To understand the molecular basis for this Cowden-spe-
cific clustering, a supervised analysis was performed
(Figure 2) identifying a molecular signature of 101 over-
expressed genes and 30 underexpressed genes in the
Cowden group (Table S2 in Additional file 1). Pathway
and Gene Ontology analyses of the Cowden tumors
(Table 1) showed enrichment for genes belonging to
several metabolic pathways, including lipid metabolism
(P = 1 × 10-10), PPARg signaling (P = 3 × 10-6) and
androgen and estrogen metabolism (P = 1 × 10-4). Com-
parison with published data [29] showed that there was
no overlap between our signature and the Agendia 70-
gene profile [30] (70 probes) or the OncotypeDx recur-
rence score [31] (16 genes), and there was only minimal
overlap with the Core Serum Response gene set [32] (5
genes in common out of 416 probes). The enrichment
in metabolic genes in the Cowden signature is reminis-
cent of molecular apocrine tumors [33], a tumor type
Figure 2 Supervised hierarchical clustering of familial breast cancers. Hierarchical clustering using 200 probe sets that distinguish the
orange branch from the other tumors in Figure 1. Table S1 in Additional file 1 lists the corresponding genes. PTEN, ESR1, PGR, AR, Sorlie, Hu: see
Figure 1.
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suspected to have increased androgenic signaling that
overlaps with the HER2 class in the Stanford classifica-
tion. In total, 54 genes are shared by the Cowden (131
genes) and apocrine (556 genes) signatures [33]. This
overlap is highly significant (P = 6 × 10-50) and substan-
tially greater than with any other signatures we tested
(Table 1). A principal components analysis (PCA) (Fig-
ure 3) with the genes of the Farmer signature [33]
showed that the tumors of our study fall into three dis-
crete groups containing the basal-like, the luminal and
the Cowden-like tumors (Figure 3C). The converse is
also true: principal components analysis of the Farmer
tumors with the Cowden genes identified six Cowden-
like tumors corresponding to the six tumors previously
labeled as molecular apocrine subtype (Figure 3B). We
conclude that the Cowden and molecular apocrine sig-
natures identify the same tumors.
GGT1 is an immunohistochemical marker for sporadic
and Cowden disease breast cancers with apocrine profile
To test whether apocrine differentiation is a general fea-
ture of Cowden disease breast cancers, we examined an
additional 12 tumors, for which RNA was not available, by
histological and immunohistochemical techniques on a tis-
sue microarray containing the 12 new and the 74 original
tumors. To identify antibodies that work on formalin-fixed
paraffin-embedded material we screened for antibodies
showing the largest difference in mean expression level
between the Cowden/apocrine tumor group and the
others. The most discriminating antibody was against
gamma-glutamlytransferase (GGT1). We also assessed
expression of the androgen receptor (AR) and the epider-
mal growth factor receptor (EGFR) because of their asso-
ciation with the molecular apocrine subtype [33,34],
GCDFP15 (PIP), a marker of apocrine differentiation cur-
rently used in routine pathological practice [33,35], PTEN
itself, and the classic markers ERBB2, estrogen receptor
alpha (ER) and progesterone receptor (PR). The results are
summarized in Table 2 and detailed in Tables S3 and S4
(Additional file 1). In the initial set of tumors, three have
histological features of classic apocrine carcinoma (cases
46, 113 and 118), one is an invasive ductal carcinoma with
apocrine features (case 96), and the remaining tumor is a
poorly differentiated invasive ductal carcinoma without
apocrine features (case 116). All of the tumors in this
group are strongly positive for GGT1 (Figure 4), and the
four tumors with histological apocrine features expressed
EGFR (cases 46, 96, 113 and 118). In the new set of Cow-
den tumors, two have histological features of classic apoc-
rine carcinoma (cases 295 and 891) and are GGT1
positive. Two are invasive ductal (cases 681 and 732), one
is a micro papillary carcinoma (case 712), all with apocrine
features that do not meet the full criteria for apocrine car-
cinoma; all three are weakly positive for GGT1. Overall, if
one uses a threshold of 1% of GGT1-stained cells to score
tumors as positive, 12 out of the 15 Cowden tumors are
positive for GGT1 and only one of 69 in the control group
(P = 9 × 10-13) (Figure 4). GCDFP15 was less useful as a
Cowden or apocrine marker since 8 of the 15 Cowden
tumors were positive, compared with 14 of the 69 control
tumors (P = 0.025) (Table 2, Tables S3 and S4 in Addi-
tional file 1, and Figure 4). The other markers showed that
typical invasive apocrine carcinomas are AR-positive, ER-
negative and EGFR positive. The Cowden tumors were all
AR-positive but only 27% were ER-negative, indicating
that the phenotype of apocrine carcinomas is not identical
to that of Cowden breast cancers. Interestingly, PTEN
immunohistochemistry was negative in 13 of the 15 Cow-
den tumors, compared to only 3 of 69 in the control
group. The two non-Cowden molecular apocrine tumors
showed clear PTEN positivity. We conclude that breast
cancers occurring in women with Cowden disease com-
monly show apocrine differentiation and that GGT1
appear to be a useful marker to identify molecular apoc-
rine carcinomas.
Molecular apocrine carcinomas have genetic alterations
of the ERBB2/PIK3CA/PTEN pathway
The main genetic lesion associated with molecular apoc-
rine carcinoma in the literature is ERBB2 amplification
Table 1 Gene ontology enrichment for the Cowden
signature and comparison with other signatures
Gene Ontology interrogation P-value
Oxidoreductase activity 3 × 10-11
Lipid metabolic process 1 × 10-10
Cellular lipid metabolic process 4 × 10-7
Carboxylic acid metabolic process 1 × 10-5
Organic acid metabolic process 1 × 10-5
KEGG pathway database interrogation
PPAR signaling pathway 3 × 10-6
Bile acid biosynthesis 6 × 10-5
Androgen and estrogen metabolism 1 × 10-4
Arachidonic acid metabolism 2 × 10-4
Metabolism of xenobiotics by cytochrome P450 4 × 10-4
MSig database interrogation
Molecular apocrine signature (Farmer et al.) 6 × 10-50
Genes upregulated by androgen in neoplastic prostate
epithelium (Nelson et al.)
1 × 10-10
Genes annotated in NetAffx as androgen related (NetAffx) 2 × 10-8
Genes downregulated in AIDS-related primary effusion
lymphoma (PEL) cells compared to normal B cells and
other tumor subtypes. (Klein et al.)
2 × 10-4
Genes downregulated by telomerase (Smith et al.) 4 × 10-4
Downregulated in mature, differentiated adipocytes
following treatment with TNFalpha (Ruan et al.)
4 × 10-4
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[33,36,37]. To identify additional lesions, we performed
array CGH of the five tumors showing a molecular
apocrine profile including the three Cowden tumors.
The results are shown in Figure 5. In contrast with typi-
cal sporadic breast cancers, the CGH profiles of molecu-
lar apocrine Cowden tumors show no major
abnormalities, with a genomic perturbation rate of 0.08,
0.05 and 0.12, respectively, for tumors 113, 116 and 118,
while apocrine non-Cowden tumors show a higher rate
of 0.27 and 0.43, respectively, for tumors 46 and 96
(Table S5 in Additional file 1). By comparison, the mean
value of perturbation rate in a series of 135 unselected
breast carcinomas is 0.28 (range 0.02 to 0.73) (unpub-
lished data). Specifically, gain or loss of large segments
of chromosome arms, a defect very commonly seen in
sporadic tumors, was only seen in three tumors, and
was restricted to chromosomes, 1, 8, 15, 16, 19 and 21
(Figure 5A). On the other hand, many small gains and
losses were observed particularly affecting chromosome
17. Only one tumor (case 96) had an amplicon on
Figure 3 Principal components analysis using the Cowden and molecular apocrine (Farmer) signatures (13). The first two principal
components were used to plot the tumors from this study in A and C, and to plot the tumors from the Farmer study in B and D. The genes
used were derived from the Cowden signature in A and B, and from the Farmer signature in C and D. In both cases, the signatures from the
two studies identify the same tumors.
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chromosome 17 that included the ERBB2 gene (Figure
5C). Interestingly, this was one of the two non-Cowden
tumors in the molecular apocrine group. One obvious
question is whether the CGH profiles for the Cowden
tumors show loss of heterozygosity for the PTEN locus.
The small genomic rearrangements observed in tumor
118 include a specific loss at the chromosomal band
10q23 that spans the PTEN gene (Figure 5B). Sequen-
cing of the corresponding tumor DNA confirmed that
the deletion eliminates the wild type PTEN allele in that
tumor. Although a slight predominance of the mutated
allele is observed for tumor 116, no clear evidence for
allelic loss was obtained from sequencing and semi
quantitative multipex PCR for the two other Cowden
tumors (data not shown). It is however difficult to defi-
nitively conclude the PTEN allelic status because of nor-
mal cell contamination that can mask a loss of genetic
material in tumoral cells. Evidence for the loss of the
wild type allele in at least one tumor suggests that
PTEN behaves like a classic tumor suppressor gene in
Cowden tumors. Further support for this model comes
from immunohistochemical staining for PTEN, which
was reduced or absent in all but the two non-Cowden
tumors in the panel tested (Table 2; Figure 4). The loss
of the PTEN protein expression associated with the
probable retention of the wild type PTEN allele in cases
113 and 116 suggests that additional changes, such as
DNA methylation, may eliminate expression of the wild
type allele in some cases.
Transcriptomic differences between Cowden tumors and
molecular apocrine carcinomas
Given the relatively flat CGH profiles of the Cowden
tumors, which contrast strongly with the expected,
amplicon-rich profiles in sporadic molecular apocrine
tumors, we performed a supervised analysis of gene
expression data to identify potential explanations for the
difference between the two tumor types. The results,
which should be treated with caution because of the
small number of tumors tested, are given in Table S6
and S7 (Additional file 1) and in Figure S1 in Additional
file 2. We identified a signature of 200 probe sets corre-
sponding to 54 genes upregulated in Cowden breast
tumors and 110 genes upregulated in non-Cowden
apocrine tumors. Pathway and Gene Ontology enrich-
ment analyses indicated that the Cowden tumors prefer-
entially express genes involved in MAPK and
JAK-STAT signaling pathways whereas non-Cowden
apocrine tumors express genes involved in insulin and
calcium signaling pathways.
Table 2 Characteristics of the Cowden breast cancers and the non-Cowden apocrine carcinomas
Tumor
sample
Cowden
disease
PTEN germline
mutation status
Age at diagnosis
of cancer
Histologic
type
Histologic
grade
Apocrine
features
AR ER PR ERBB2 GCDFP15 GGT1 PTEN
46 No WT 60 y IAC 2 Yes 2 0 0 0 2 2 2
96 No WT 40 y IDC 3 Yes 2 0 0 +++ 2 2 2
113 Yes c.209+5G > A 48 y IAC 1 Yes 2 0 0 0 2 2 0
116 Yes c.1007dupA p.Tyr336X 44 y IDC 2 No 2 2 2 0 0 2 0
118 Yes c.209+5G > A 35 y IAC 2 Yes 2 0 0 0 2 2 0
S89 Yes c.158_159insATAC p.
val54TyrfsX10
44 y IDC 2 No 2 2 2 0 0 0 0
S243 Yes c.323T > C p.
Leu108Pro
28 y IDC 2 No 2 2 2 0 0 1 0
S295 yes c.209+5G > A 44 y IAC 2 Yes 2 0 0 0 2 2 0
S362 Yes c.69dupA p.
Asp24ArgfsX20
53 y DCIS low No 2 2 2 0 0 1 0
S403 Yes c.801+1delG 43 y IDC 2 No 2 2 2 0 0 0 0
S574 Yes c.491delA p.
Lys164ArgfsX3
46 y IDC 1 No 2 2 2 0 0 1 0
S681 Yes c.830C > G p.
Thr277Arg
27 y IDC 3 Yes 2 2 1 + 1 1 0
S712 Yes c.592delA p.Met198X 41 y MPC 2 Yes 2 2 0 nd 0 1 0
S730 Yes c.493G > A p.
Gly165Arg
59 y ILC 2 No 2 2 2 + 2 0 0
S732 Yes c.510T > G p.
Ser170Arg
46 y IDC 2 Yes 2 2 2 0 1 1 1
S891 yes c.209+5G > A 35 y IAC 2 Yes 2 0 0 ++ 2 2 2
S912 Yes c.632_633delGC p.
Cys211X
34 y IDC 2 No 2 2 2 0 1 1 0
IHC status excepted for ERBB2 (0 to +++): 0 = negative; 1 = positive up to 10% of cells; 2 = positive above 10% of cells. DCIS, ductal carcinoma in situ; IAC,
invasive apocrine carcinoma; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MPC, micro papillary carcinoma; nd, not determined; WT, wild type.
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Discussion
The main conclusion from this study is that germline
PTEN mutation predisposes to the formation of breast
tumors with apocrine features. This is intriguing because
of the large body of work linking ERBB2, PTEN and
PI3-kinase signaling to breast cancer. Interestingly, the
timing of PTEN loss during tumorigenesis seems to dic-
tate the phenotype, with apocrine features particularly
associated with germline PTEN loss.
In the original microarray-based classification of breast
cancer, Perou and colleagues identified a group of
tumors enriched in ERBB2-amplified tumors that they
called the HER2 class [1]. Further analysis of this group
on Affymetrix gene expression arrays, which have a
broader selection of genes than was available to Perou,
confirmed the observation that ERBB2 is commonly
amplified [1,3,4], but we proposed the name molecular
apocrine for the group to reflect the RNA phenotype
[33] and the fact that many ERBB2-amplified tumors lie
outside this group. The results of the present study con-
firm the existence of a molecular apocrine group, and
further weaken the argument for using HER2 to label it,
because the tumors with this phenotype showing germ-
line PTEN mutations lack ERBB2 amplification.
Apocrine carcinoma is a classic histological subtype of
breast carcinoma with characteristic morphological and
immunohistochemical features [38,39]. It belongs to a
spectrum of apocrine metaplasia including common
benign conditions like fibrocystic disease that are asso-
ciated with increased androgen signaling. In general, the
link with androgens is stronger at the benign end of the
spectrum, but some malignant tumors in the apocrine
group also show increased expression of androgen
receptor target genes, and a breast cancer cell line
Figure 4 Immunohistochemical analysis of the whole panel of breast tumors. Sections of three breast tumors occurring in patients with
Cowden disease showing negative staining for PTEN (B, F, J), positive staining scored 2 for GCDFP15 (C) and GGT1 (D), positive staining scored
1 for GCDFP15 (G) and GGT1 (H) and negative staining for GCDFP15 (K) and GGT1 (L). The proportion of tumors showing positive staining for
these proteins in Cowden tumors (n = 15), molecular apocrine tumors (n = 5) and the remaining familial breast cancers (n = 69) is shown in (M
to O). See material and methods for attribution of scores 0, 1 and 2.
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(MDA-MB-453) with a molecular apocrine gene expres-
sion profile was recently shown to be androgen-depen-
dent for growth [36]. Interestingly, this cell line has an
inactivating PTEN mutation (c.919G > A - p.Glu307Lys)
[40]. Classic apocrine carcinoma is not known to be
linked to Cowden disease, but benign mammary lesions
occurring in Cowden disease frequently show apocrine
differentiation [41,42], and 4 of the 15 tumors in our
series met the full histological criteria for a diagnosis of
apocrine carcinoma. The original molecular apocrine
description linked this subtype of tumors to the AR
positive and ER negative phenotype. In this series, sev-
eral Cowden tumors, including tumor 116 that belongs
to the Cowden/apocrine transcriptomic cluster are ER
positive. This tumor may be an example of the recently
described apocrine-like carcinoma which includes AR
and ER positive tumors [34]. Additional transcriptomic
studies of Cowden breast carcinoma will be necessary to
confirm and extend this hypothesis.
The two non-Cowden apocrine carcinomas in this
study express a normal level of wild type PTEN, indicat-
ing that some other mechanism must explain the apoc-
rine differentiation of these tumors. Interestingly, one of
these tumors has amplified the ERBB2 gene and the
other has a PIK3CA mutation (c.3140A > G; p.
His1047Arg - data not shown). Thus, all five apocrine
tumors for which we have RNA, DNA and immunohis-
tochemical data show a specific genetic alteration in the
ERBB2-PTEN-PIK3CA pathway. This observation seems
to indicate that if the main phenotypic trait of apocrine
Figure 5 Array CGH of the five molecular apocrine tumors. Graphical view (VAMP software) showing the log2 ratio of the fluorescence
intensities for each clone. Gains appear in red, amplicons in blue, losses in green and balanced signals in yellow. (A) Pan genomic array CGH
profile of the Cowden (n = 3) and non-Cowden (n = 2) molecular apocrine tumors. (B) Plot of chromosome 10 showing genomic loss in sample
118 at the PTEN locus. The pink bar and the black line indicate respectively the PTEN locus and the centromere position. (C) Plot of chromosome
17 showing amplicons in sample 96. The proximal amplicon at 17q12 contains the ERBB2 gene as indicated by the pink bar.
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carcinomas is increased androgen signaling, the main
genetic trait is mutation of genes in the ERBB2-PTEN-
PIK3CA pathway. The number of tumors is too small to
draw a definitive conclusion but the observation is pro-
vocative and deserves further study.
The link between PTEN and apocrine differentiation
seems not to extend to somatic PTEN mutations.
Although rare, somatic PTEN mutations have previously
been reported in breast cancer [43,44], but they were
seen mainly in the basal-like tumors class characterized
by a loss of expression of PTEN [45] and more specifi-
cally in tumors from patients with BRCA1 mutations
[40]. The 74 familial breast cancers microarrayed in this
study include seven linked to BRCA1 and five linked to
BRCA2. None of these tumors has a molecular apocrine
profile. In the same way, tumors 9, 11 and 15 have lost
PTEN expression (Table S2 in Additional file 1) but do
not have a molecular apocrine profile (luminal A for
tumors 9 and 11; basal-like for tumor 15). Thus, somatic
PTEN mutation appears not to be directly linked to
apocrine differentiation in our panel of familial tumors.
To formally exclude a role in sporadic tumors, a specific
study of PTEN alterations in sporadic apocrine carci-
noma should be done.
The mechanism leading from germline PTEN muta-
tion to apocrine differentiation is unknown, but there
are numerous hints in the literature. First, PTEN has
been shown to inhibit androgen receptor-driven tran-
scription in LNCaP prostate cancer cells in an AKT-
dependent or independent manner [46,47]. Loss of
PTEN in this model increases androgen signaling, which
is itself a feature of apocrine cells. Second, ERBB2
amplification is commonly seen in sporadic tumors in
the molecular apocrine class. ERBB2 has been shown to
stabilize AR protein in prostate cancer cells [48] and to
activate the Akt pathway [49]. Third, in a large-scale
RNA interference screen, PTEN silencing conferred
resistance to trastuzumab in breast cancer cells with
ERBB2 amplification [50]. Fourth, PTEN-deficient/
Erbb2KI transgenic mice show accelerated mammary
tumor onset associated with elevated ERBB2 protein
levels that are not caused by ERBB2 amplification [51].
A subset of the mouse tumors has large nuclei, promi-
nent nucleoli and abundant cytoplasm, the hallmarks of
apocrine histology. This confirms that increased ERBB2
signaling in the context of germline PTEN loss predis-
poses to apocrine tumorigenesis, and provides a trans-
genic mouse model to study apocrine breast cancer.
Finally, the Gene Ontology analysis in Table 1 links the
Cowden signature to increased PPARg signaling. PPARg
has previously been linked with the PTEN pathway [52],
it transactivates the PTEN promoter [53], and PPARg
agonists increase PTEN expression in breast cancer cell
lines. Activation of the PPARg pathway following loss of
PTEN could be explained by negative feedback of PTEN
on PPARg.
Conclusions
Taken together, our results in Cowden disease and mul-
tiple results in the literature strongly support a central
role for the ERBB2-PTEN-PIK3CA-AKT pathway in the
biology of breast cancer. We suspect that loss of PTEN
early in tumorigenesis leads to the expansion of a cell in
the hierarchy of mammary differentiation with a pro-
nounced tendency to undergo apocrine metaplasia. Cur-
rent models for mammary differentiation would place
this cell at a late point in the hierarchy, after the luminal
progenitor stage [54].
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